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ABSTRACT
TOBACCO-DERIVED ALDEHYDES: PLATELET ACTIVATION, THROMBOSIS,
AND THE ROLE OF TRPA1
Andre Dwyane Richardson
November 12, 2019

Cigarette smoking is the single largest risk factor for cardiovascular
disease (CVD) pathophysiology. Numerous researchers have shown potential
associations between aldehydes in tobacco-derived aerosols from mainstream
cigarette smoke (MCS) or electronic cigarettes (e-cigs) and their cardiotoxicity by
damaging blood vessel endothelium. The severity of exposure to these toxicants
can furthermore lead to adverse cardiovascular outcomes such as myocardial
infarctions, stroke, coronary and peripheral artery disease, or atherosclerosis due
to blood clots, a pro-thrombotic event. However, the mechanisms by which levels
of harmful and potentially harmful constituents (HPHCs) such as aldehydes
induce thrombosis are not well-known. Of specific interest, evidence has shown
that smoke exposure enhances platelet sensitivity and activation. Thus, the
purpose of this project is to examine the effects of exposure to MCS, e-cigs, as
well as their constituent saturated and unsaturated aldehydes, and flavoring
additives on platelet activation as a marker of thrombosis.
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CHAPTER 1:
INTRODUCTION

1.A. Cardiovascular Disease (CVD) & Tobacco Smoking
Cardiovascular diseases are a collective of pathological changes involving
the structure and function of the heart and/or the blood vessels [1], and CVD are
a major public health concern. Coronary heart disease (CHD), a type of CVD, is
most prominently caused by atherosclerosis that occurs due to cholesterol and
fatty deposits building along the arterial wall [2, 3]. This action causes plaque
accumulation, narrowing of arteries leading to hypertension [1, 3], and thus
increasing the risk of atherosclerosis, myocardial infarction (MI), and stroke. Also
regarded as the leading death causing disease in the U.S. as well as worldwide
[4], CVD claims more lives each year than all forms of cancer and chronic
respiratory diseases combined and also accounts for approximately 610,000
related deaths every year, which is one out of every four deaths. Related to
public health, the costs associated with CVD total more than $316 billion in
health expenditures and lost productivity and is expected to rise to >$1 trillion
dollars by the year 2030 [4]. These statistics demonstrate the severity of CVD as
both significant health and financial concerns for the public.
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As noted by the Centers for Disease Control and Prevention (CDC) and
the American Heart Association (AHA), smoking harms nearly every organ of the
human body, causing many diseases, and significantly reducing an individual’s
overall health with chronic use as well as to those around them due to
secondhand smoke exposure [5-8]. Smoking is reported as the leading
preventable cause of severe illnesses and premature death in the U.S. [9, 10].
Smoking contributes to more than 440,000 deaths each year, accounting for 30%
of CVD-related deaths in the U.S.
Tobacco smoking exacerbates plaque build-up along blood vessel walls
[11] as a result of the tobacco-derived chemical constituents causing
hypercoagulability in the blood and platelets to activate. This leads to formation
of a thrombus within the vessels. This pathophysiologic outcome manifests in the
form of MI, stroke, and thrombosis. Moreover, stroke alone is characterized as an
impairment of cerebral cognition and function due to lack of blood reaching the
brain [12]. It has been reported that current smokers are at a significantly higher
risk of stroke compared with individuals who have never smoked or are former
smokers [13-16].

1.B. The Prevalence of Electronic Cigarettes
Smoking devices such as electronic cigarettes (e-cigs) impose a new
threat to public health and have been linked to increased risk of developing CVDrelated illnesses [17, 18]. In the U.S., the development of “next-generation” e-cigs
in 2007 has prompted a completely different public health burden. Conventional
2

tobacco usage was at a decline, but an increased use of e-cigs was observed
with an initial claim that these were a healthier substitute [19, 20]. Compared with
conventional tobacco products, e-cigs are considered electronic nicotine delivery
systems (ENDS) since these do not typically contain tobacco [21]. These
products are marketed specifically towards youth and young adults. The concern,
however, is that by using these products, the potential for renormalizing use of
conventional tobacco products is increased as well as CVD-risk [19]. The
common misconception is that e-cigs are less toxic because they contain far less
non-carcinogenic ingredients and do not produce highly toxic aerosols compared
with those of conventional cigarettes [22]. Conventional tobacco cigarettes
contain hundreds of ingredients (e.g. nicotine and cardiotoxic heavy metals), and
during combustion, the smoke that is generated consists of a complex mixture of
more than 7,000 toxic chemical constituents (e.g. aldehydes, polycyclic aromatic
hydrocarbons, carbon monoxide, oxidants, ammonia, and tar) [23].
Approximately 70 of the known constituents of these products are known
carcinogens and/or are poisonous [23]. On the other hand, e-cigs contain eliquids with the following ingredients: propylene glycol (PG), vegetable glycerin
(VG), nicotine, and various flavoring additives [24]. Around the time e-cigs were
introduced, these e-liquids were thought to be nontoxic because either they did
not contain toxic byproducts or they did not produce these toxins at levels near
those present in or derived from tobacco combustion [25-27]. However, Sassano
et al. showed that chemicals in e-liquids do have toxic effects by negatively
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affecting cell viability [27]. Additionally, nicotine is an addictive substance with
severe health risks [28, 29].

1.C. Toxicity of Tobacco-Derived Aldehydes and Flavors
In a conventional tobacco cigarette, smoke generated by combustion
contains toxic reactive aldehydes, specifically formaldehyde, acetaldehyde,
acrolein, and crotonaldehyde. These are also known as harmful or potentially
harmful constituents (HPHCs) [30]. On the other hand, when taking a puff from
an e-cig, the e-liquids are then heated and generate an aerosol containing the
same toxic reactive aldehydes as a result of a thermal dehydration reaction of the
e-liquids [31]. Although acrolein and crotonaldehyde are not typically produced in
e-cig aerosols, or produced at much lower levels compared with conventional
tobacco smoke, there are proposed mechanisms by which PG/VG produces
these unsaturated aldehydes as well [32]. VG produces acrolein, the simplest
unsaturated aldehyde [32, 33]. PG generates saturated aldehydes such as
formaldehyde, acetaldehyde, and propionaldehyde [32, 33]. Varying
concentrations of these aldehydes are generated depending on the e-cig battery
voltage [31, 34]. Furthermore, the various concentrations of aldehydes in e-cig
aerosols are associated with a number of cardiovascular risks such as cardiac
oxidative stress, DNA damage in bone marrow, increased platelet counts, and
increased blood coagulation via platelet activation [35]. Acrolein, a common air
pollutant, specifically has certainly been associated with increased CVD-risk [36,
37] and has been shown to increase thrombosis activate hemostasis via platelet
4

activation [38], promote platelet-leukocyte aggregate formation and also forms
adducts with platelets [38], though the mechanism is unclear. Although many
health implications have been discussed concerning aldehydes derived from ecig vaping, there is not a clear, defined relationship between the toxic aldehydes
and the risk these impose on CVD.
1.C.i. Formaldehyde:
Formaldehyde is the simplest aldehyde and is gaseous at room
temperature; it is colorless with a pungent, irritating odor. According to the
National Toxicology Program (NTP), formaldehyde is a known human carcinogen
[39]. In terms of the cardiotoxic effects that are associated with formaldehyde
exposure, it has been shown that high levels of formaldehyde induce
vasopressor effects in anesthetized rats, or an increase in blood pressure as a
result of a blood vessel undergoing contraction [40]. Conversely, lower levels of
formaldehyde in rats result in hypotension [40].
1.C.ii. Acetaldehyde:
According to the NTP, acetaldehyde is a reasonably anticipated human
carcinogen [41]. It has also been shown that acetaldehyde induces hypertension
at high concentrations (≥3.0 µg/mL) in inhalation-exposed rats [42]. Similar
results are observed when acetaldehyde is administered via intraperitoneal
injection (5-20 mg/kg) with a decrease in heart rate [43-45].
1.C.iii. Acrolein:
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Acrolein is a well-researched environmental toxicant and air pollutant
which is generated as a result of burning and high temperature fumes [46, 47].
Acrolein, which can also be generated from VG degradation, is an α,βunsaturated aldehyde, a known eye irritant, a respiratory and cardiovascular
toxicant [46], and a major constituent of cigarette smoke [48]. Acrolein also
induces vasopressor effects as demonstrated by Egle et al. 1974 in their study of
intravenously-injected rats. While acrolein up to 0.25 mg/kg caused rapid
hypertension [40], hypotension resulted from exposure at higher levels (>0.25
mg/kg) [40]. Exposure to acrolein via inhalation exposure also causes high blood
pressure [40].
1.C.iv. Crotonaldehyde:
Crotonaldehyde is an α,β-unsaturated aldehyde with a pungent,
suffocating odor. Inhaled crotonaldehyde is toxic at low concentrations and
causes irritation within the upper respiratory tract [49]. The Occupational Safety
and Health Administration (OHSA) imposed a 2 ppm exposure limit to
crotonaldehyde over an eight-hour workshift, but levels between 0.035 ppm and
0.12 ppm induce toxicity [50]. Although much remains unknown about the
cardiotoxicity associated with crotonaldehyde exposures, we hypothesize that
this compound could potentially induce vasopressor effects in a similar fashion
as acrolein due to their similarities in their chemical structures.
For the purpose of this research, we will study formaldehyde,
acetaldehyde, acrolein, and crotonaldehyde as these are the foremost toxic
aldehydes present in tobacco and e-cig aerosols, and thus, may contribute to
6

CVD-risk and noncancerous pulmonary disease. In our preliminary studies, we
tested the effects of aldehyde exposure on platelet aggregation ex vivo as well as
on platelet-leukocyte aggregate (PLA) formation in vivo.
1.C.v. E-Cig Flavoring Additives:
Today, the craze surrounding the e-cig market is the development and
usage of flavorings. A variety of flavorings such as clove oil, cinnamon, vanilla,
and mint allow e-cigs users to choose a desired sweetener for consumption.
When heated using an e-cig, the chemical products (e.g. eugenol,
cinnamaldehyde, vanillin, and menthol) may exacerbate CVD-risk [33]. This
alone creates new alarms in that flavorings may contribute to adverse
cardiovascular outcomes. A study published in 2018 revealed a remarkable
finding that in fact nine flavoring products induce cardiotoxicity via endothelial cell
dysfunction [51]. Fetterman et al. exposed human aortic endothelial cells to nine
different flavoring compounds and found that these flavors induced dysfunction to
the endothelium via cell death, oxidative stress, increased inflammation, and
decreased nitric oxide (NO) production [51]. NO is well known to inhibit platelet
activation [52-55], suggesting if NO is diminished due to flavoring exposure, the
likelihood of platelet activation is significantly increased [56]. However, this idea
that flavors induce platelet activation has yet to be fully investigated. In our
preliminary study, we tested the effects of e-cig flavorings on adenosine
diphosphate (ADP)-induced biphasic platelet aggregation ex vivo (see Materials
& Methods).
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1.D. Pathophysiology of Platelet Activation/Thrombosis
Platelets are small (2-3 µm in diameter) circulating fragments of
megakaryocytes in the blood that play an important role in hemostasis,
thrombosis, and inflammation [57]. Platelets aid in maintaining vascular integrity
within an injured blood vessel via forming adducts with leukocytes, thus creating
clots [57, 58]. Quiescent platelets circulate throughout the vasculature until
recruited to sites of vascular injury or damage, where they become activated [57].
Once activated, platelets undergo an initial shape change and secrete their αgranule and dense granule contents via exocytosis or granule secretion. When
this occurs, a number of catecholamines (e.g. adenosine diphosphate (ADP),
adenosine triphosphate (ATP), serotonin, histamine, and calcium [59]) are
released into circulation and bind to surface receptors of other nearby platelets
[60]. This initiates a cascade of signaling mechanisms, platelet activation, and
aggregation ultimately leading to formation of a platelet plug, preventing further
bleeding and/or hemorrhaging.
Thrombosis is described as the formation of a thrombus, or clot. Deep
vein thrombosis (DVT), venous thromboembolisms, and pulmonary embolisms
are all influenced by platelet aggregates. It is well known that smoking is a risk
factor for the development of thrombosis. As demonstrated by Morris et al. and
other investigators, traditional cigarettes and e-cig smoking strongly impacts the
turnover, structure, activation, and function of platelets [17, 61]. Each of these
pro-thrombotic actions contribute to CVD-related morbidity and mortality.
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1.E. Importance of Study
Hypothesis: Tobacco-derived constituents induce platelet activation as
observed by potentiated biphasic platelet aggregation ex vivo and increased
platelet-leukocyte aggregate (PLA) formation in vivo.
Aim 1: Test the concentration-dependent influence of tobacco-derived
acrolein and flavorings on phase-specific ADP-induced platelet aggregation.
Aim 2: Examine the level- and duration-dependent effects of exposure to
mainstream cigarette smoke (MCS), e-cig aerosol, and aldehydes on PLA
formation.
Exposure to acrolein activates hemostasis and pro-thrombotic events via
platelet activation. Exposure to acrolein from smoking induces the formation of
PLAs and also forms adducts with the platelets themselves [38], though the
mechanism is unclear. Thus, we aim to determine the specific contribution of
aldehydes and flavorings in smoking products to platelet activation in order to
better define the relationship between these toxins and CVD-risk. Platelets
undergo a cascade of events following activation (e.g. adhesion, aggregation,
and complex formation with leukocytes leading to platelet plug formation), and
these could all be influenced by interaction with inhaled tobacco constituents.
Platelet adhesion is the first action of platelet activation upon blood vessel injury
involving platelet surface receptor protein interactions with collagen in the subendothelium [62]. Platelet aggregation is the second action of platelets following
release of granules and catecholamines in order to form clots [63], addressed in
the first specific aim. PLAs are those complexes formed with leukocytes upon
9

adhesion and aggregation at the site of blood vessel injury [38, 58, 64],
addressed in the second specific aim. Each specific aim is significant in that they
will help to better define the mechanism of tobacco smoke-induced
cardiovascular toxicity, specifically regarding platelet activation. Furthermore, we
aim to determine the levels of aldehyde- and flavor-containing aerosols capable
of inducing unwarranted thrombotic events.

1.F. SUMMARY
We are proposing that cigarette smoke and vaping exposure induces
cardiotoxicity via platelet activation. Taken together, the results of this proposed
preliminary research will help our understanding of these tobacco products and
how they potentially threaten cardiovascular health. Since the development of ecigs, there is an urgent need to address the potential cardiotoxic outcomes that
may result from using these products. Many researchers have addressed
carcinogenic and pulmonary outcomes from using e-cigs [65-68], however, more
research is needed to gain knowledge about the cardiovascular-related
outcomes, adding to the significance and impact of this research.
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CHAPTER 2:
MATERIALS & METHODS

2.A. ADP-induced Platelet Aggregation in vitro via Platelet Aggregometry
Assay:
The dynamism of platelets has long been studied via a number of different
platelet function assays and methodologies [69]. The platelet aggregometry
assay is the most widely accepted, gold standard platelet function assay that
utilizes human platelet rich plasma (PRP) of whole blood. This method measures
the ability of different stimuli to induce platelet-platelet aggregation ex vivo.
Using the ex vivo platelet aggregometry assay, the direct effects of the
various concentrations of acrolein and e-cig flavoring compounds on ADP-induced
platelet aggregation were assessed. Human biorepository blood were collected in
top citrate tubes. Human PRP was be obtained via centrifugation (180 xg, 12 min)
of whole blood for use in this assay. A ChronoLog aggregometer was used to
measure aggregation photometrically post-ADP induction over five minutes. Fifty
microliters of PRP were used to obtain a platelet count. The remaining blood was
centrifuged again for 20 minutes at 1,300 xg in order to obtain the platelet poor
plasma (PPP) used as a reference sample in each experiment. Additionally, we
wanted the platelet concentration of PRP to be 3.00 x 108 plt/mL. From the platelet
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counts, if the concentration was above this limit, we used the PPP to dilute the
PRP using the equations below:

[𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑖𝑛 𝑃𝑅𝑃] 𝑥 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑃𝑅𝑃 (𝑚𝐿)
[𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑖𝑛 𝑃𝑅𝑃]
= 𝐹𝑖𝑛𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑃𝑅𝑃 (𝑚𝐿)

𝐹𝑖𝑛𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑃𝑅𝑃 − 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑃𝑅𝑃
= 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑃𝑃𝑃 𝑡𝑜 𝑎𝑑𝑑 𝑡𝑜 𝑃𝑅𝑃 𝑡𝑜 𝑜𝑏𝑡𝑎𝑖𝑛 3.00 ∗ 108

𝑝𝑙𝑡
𝑚𝐿

Following this procedure, varying concentrations (10, 30, 300, and 100 µM) of
acrolein along with 10, 25, 50, and 100 µM concentrations of e-cig flavoring
additives (eugenol, cinnamaldehyde, vanillin, and menthol) were tested to observe
their effects on ADP-induced platelet aggregation using the aggregometer. Three
hundred fifty microliter aliquots of PRP were placed into sample cuvettes within
each of the four channels of the aggregometer and incubated for five minutes at
37 ºC with continuous stirring at 1,000 rpm. Next in the test/control run, the
aggregation response of the platelets with ADP (2.5 or 10 µM) were observed.
ADP was added to each sample, and we monitored and calculated the
biphasic aggregation responses as phase 1 and phase 2 for an additional five
minutes. Again, at resting state, our platelets were incubating with our
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constituent/chemical of choice for five minutes. Once ADP was added, it initiated
a shape change followed by the phase 1 response solely due the stimulant. During
phase 1, the alpha and dense granules are secreting, and the secondary response
is being amplified due to other platelets becoming activated and starting to
aggregate together, which is the phase 2 response. We recorded total aggregation,
phase 1 and phase 2 as percentages using the equation below.

𝑇𝑜𝑡𝑎𝑙 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑖𝑜𝑛 (%) = 𝑃ℎ𝑎𝑠𝑒 1 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑖𝑜𝑛 (%) + 𝑃ℎ𝑎𝑠𝑒 2 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑖𝑜𝑛 (%)

In each of the following sample runs, each channel contained either ADP alone
(positive control), ADP with acrolein, or ADP with an e-cig flavorant. We
hypothesized that the compounds in question would enhance the sensitivity of the
platelets directly.
Statistical Analysis:
Data analysis was performed using a paired Student’s t-test in order to evaluate
and compare differences in the mean percent responses of total, phase 1, and
phase 2 aggregation of acrolein or flavorings with respect to control (ADP-only).
Statistical significance was accepted at p<0.05.

2.B. Platelet-Leukocyte Aggregates (PLA) in vivo via Flow Cytometry:
2.B.i. Mice Inhalation Exposure System:
13

As described by Conklin et al. 2017 [70], we obtained C57BL/6J male and
female mice from Jackson Laboratories and used them at 12 weeks of age. The
mice were housed under pathogen-free conditions in the University of Louisville
vivarium under controlled temperature and 12 h light: 12 h dark cycle. For the
exposure system, the mice were exposed to either HEPA-filtered air (control) or
aldehyde (specified aerosol, concentration, and duration of exposure) using a
custom exposure system and certified permeation tubes as described by O’Toole
et al. 2014 [71]. Immediately after completion of final exposure, the mice were
anesthetized with sodium pentobarbital (150 mg/kg) followed by ventral
thoracotomy and exsanguination via cardiac puncture for blood collection in
EDTA (0.2 M; 20 µL)-coated syringes (22G in diameter). The blood was
transferred into in EDTA coated microcentrifuge tubes and kept on ice until
aliquotted for plasma, CBC, or for preparation of flow cytometry analysis. We
also performed CBC and looked at platelet numbers and platelet volume.
2.B.ii. Mainstream Cigarette Smoke and E-Cig Aerosol:
Adult C57BL/6 male mice underwent an acute (6h/d, 4d) whole body
exposure to HEPA-filtered air (control), mainstream cigarette smoke (MCS; 3R4F
reference cigarettes; 12 cig/d) or e-cig aerosol (blu+; 6 h/d, 4d) via inhalation
(see Figure 1). As detailed by Conklin et al. 2018, a software-controlled
(FlexiWare) cigarette-smoking robot (CSR) (SCI-REQ; Montreal, CAN) system
was used to generated cigarette smoke aerosols from KY Reference cigarettes
(3R4F) and e-cig cartridges (blu®) [32]. Our MCS exposure followed the
International Standard of Organization (ISO) protocol (i.e. 2 s puff, 35 mL puff, 1
14

puff/min, 9 puffs/cigarette, 2 cigarettes/h) [32]. Our e-cig exposure consisted of
13 e-cig sessions per 4h exposure. Each session (9 min; same duration as 1
cigarette) had 18 puffs (4 s puff, 91 mL puff, 2 puffs/min) [32]. After the final
exposure, the mice were immediately euthanized and peripheral blood collected
and used in flow cytometry to detect CD45+/CD41+ PLAs.

2.B.iii. Aldehyde exposures:
C57BL/6 male and female mice were placed into a sealed chamber which
allowed for an aldehyde-like atmosphere for the mice to inhale during a
continuous exposure of aldehyde for a specified duration (see Figure 2). Control
mice were placed into similar chambers in which they were exposed to HEPAfiltered air.
2.B.iv. Statistical Analysis:
Data are reported as mean ± standard error. For statistical comparison
between two groups, the Mann-Whitney U test was used. Significance was
accepted where p<0.05.
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Figure 1. E-cig inhalation exposure system. The pump draws out vapor from the
e-cig and transfers the vapor into the exposure chamber in which the C57BL/6
male mice are contained during exposure. The MCS exposure has a similar set up
for transferring smoke to mice in the exposure chamber, but MCS exposure
involves 12 3R4F reference tobacco cigarettes following ISO protocol (i.e., 2 s puff,
35 mL puff, 1 puff/min, 9 puffs/cigarette; 2 cigarettes/h [32]. The total suspended
particulate (TSP) matter was monitored in real time with an inline infrared forward
scattering monitor (MicroDust Pro; Casella CEL Ltd., Bedford, UK).
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Figure 2. Aldehyde inhalation exposure system. C57BL/6 male or female mice are
placed inside a sealed exposure chamber. Steady, continuous 6h flow of aldehyde
gas is pumped via certified permeation tubes (Kin-Tek; LaMarque, TX) into the
chamber per specified duration in each study [71, 72]. During exposure, aldehydes
are monitored continuously with an in-line calibrated photoionization detector (PID;
ppbRAEPlus, Rae Industries, Sunnyvale, CA) [72].
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2.B.v. Formaldehyde:
Adult male and female C57BL/6 mice underwent an acute (6h/d, 4d or
2wk) exposure to HEPA-filtered air (control) or formaldehyde (2 or 5 ppm) via
inhalation. After the final exposure, the mice were immediately euthanized and
peripheral blood collected and used to detect CD45+/CD41+ PLAs by flow
cytometry.
2.B.vi. Acetaldehyde:
Adult male and female C57BL/6 mice underwent an acute exposure (6
h/d, 4d or 2wk) exposure to HEPA-filtered air (control) or acetaldehyde (5 ppm)
via inhalation. After the final exposure, the mice were immediately euthanized
and peripheral blood collected and used to detect CD45+/CD41+ PLAs by flow
cytometry.
2.B.vii. Crotonaldehyde:
Adult male and female C57BL/6 mice underwent an acute (6h/d, 4d) or
chronic (12wk, 6h/d) exposure to HEPA-filtered air (control) or crotonaldehyde (1
ppm) via inhalation. After the final exposure, the mice were immediately
euthanized and peripheral blood collected and used to detect CD45+/CD41+
PLAs by flow cytometry.
Activated platelets not only bind to endothelium and to other platelets, but
they also bind to leukocytes [58, 64, 73]. PLAs are one of the in vivo markers of
thrombosis. As previously described by Sithu et al. [38], the PLAs were quantified
as events double positive for CD41 (platelets) and CD45 (leukocytes) by flow
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cytometry. For this, 100 microliter aliquots of male or female mouse whole blood
were diluted with 400 µL of HEPES-Tyrodes solution before being fixed using
16% paraformaldehyde (50 µL) at room temperature for 30 minutes. Red blood
cells were then lysed by dilution with milliQ water (2 mL), and the lysed cells
were collected by centrifugation at 400 x g for five min then decanted. The
remaining cells were incubated (4 ºC) with 1% Fc Block (5 µL) for 10 min before
staining with FITC-labeled anti-CD41 and APC-labeled anti-CD11b or isotype
matched negative controls (FITC IgG1 and APC IgG2b kappa) for additional 30
min. Stained cells were washed with HEPES-Tyrodes (1 mL) solution containing
1% BSA, centrifuged at 400 x g for five minutes and resuspended in HEPESTyrodes solution (250 µL). A BD LSR Flow Cytometer (BD Biosciences; San
Jose, CA) was used to analyze the stained cells, and 20,000 CD45+ events were
collected from each sample. A FlowJo v10 (FlowJo, LLC) software was used to
gate for our PLAs. We began with gating for our CD45+ leukocytes using side
scatter. Then, the IgG negative control assisted in determining where to place the
CD41+ platelet gate. Thus, our PLAs were identified in quadrant 2 (Q2).
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CHAPTER 3:
RESULTS

3.A. Direct effect of acrolein on ADP-induced phase 1 and phase 2
aggregation ex vivo. The current study explores the biphasic platelet
aggregation responses to concentration-dependent acrolein exposure. Sithu et
al. completed a study in which mice were fed acrolein (1-5 mg/kg/day) for 1-3
days, and their blood collected and pooled to measure ADP-induced platelet
aggregation. They found that acrolein augmented ADP-induced aggregation [74].
The present study solely explores direct exposure of acrolein to human platelets.
Our data shows acrolein has no effect ADP-induced total aggregation, which has
been previously published [75]. Furthermore, only low concentrations of acrolein
(10 and 30 µM) induce a decrease in phase 1 and an increase in phase 2
aggregation (Figure 3).
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Figure 3. Concentration-dependent effects of vegetable glycerin-derived acrolein
on ADP-induced platelet aggregation. A) Acrolein (10 µM) and ADP (2.5 µM)
tested versus ADP-alone control; B) Acrolein (30 µM) and ADP tested versus
ADP-only control. Arrows indicate the inflection point between phase 1 and
phase 2 aggregation. C) Summary data of concentration-dependent effects of
acrolein on ADP-induced platelet aggregation. Using a paired Student’s t-test,
the percent responses of total, phase 1, and phase 2 aggregation of acrolein
were compared with respect to their control. Statistical significance was accepted
where p<0.05. This study only found biphasic changes at 10 µM and 30 µM
concentrations compared with control.
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3.B. Direct effect of clove oil-derived eugenol on ADP-induced phase 1 and
phase 2 platelet aggregation ex vivo. We are interested in how flavors from
vaping may influence pro-thrombotic events. A study by Muthumalage et al. 2017
investigated respiratory outcomes associated with exposure to different e-cigderived flavoring compounds, without the presence of nicotine [76]. Though
ingestion of these flavorings is potentially safe, the study revealed that
consumption of flavors via inhalation is not recommended. We hypothesized that
direct exposure to eugenol (clove oil) induces significant changes in biphasic
platelet

aggregation

ex

vivo.

We

found

that

eugenol

exhibited

platelet/inhibitory responses at each concentration tested (Figure 4).
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Figure 4. Concentration-dependent effects of clove oil-derived eugenol on ADPinduced platelet aggregation. A) Eugenol (10 µM) and ADP (10 µM) tested versus
ADP-alone control; B) Eugenol (100 µM) and ADP tested versus ADP-only control.
Arrows indicate the inflection point between phase 1 and phase 2 aggregation. C)
Summary data of concentration-dependent effects of eugenol on ADP-induced
platelet aggregation. Using a paired Student’s t-test, the percent responses of total,
phase 1, and phase 2 aggregation of eugenol were compared with respect to their
control. Statistical significance was accepted where p<0.05. This study found
significant inhibition at each concentration compared with control. However, no
change in phase 1 was observed.
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3.C. Direct effect of cinnamon- and vanilla-derived cinnamaldehyde and
vanillin on ADP-induced phase 1 and phase 3 platelet aggregation ex vivo.
Muthumalage et al.

2017 also found that e-cig-derived cinnamaldehyde and

vanillin were the two most toxic compounds, causing both inflammatory and
oxidative responses in vitro [76]. The present study investigates these two flavoring
compounds

known

to

induce

some

cardiovascular-related

events.

We

hypothesized that direct exposure to eugenol (clove oil), cinnamaldehyde
(cinnamon), vanillin (vanilla), or menthol (mint) induces significant changes in
biphasic platelet aggregation ex vivo. We found that cinnamaldehyde (Figure 5)
and vanillin (Figure 6) exerted no effects on ADP-induced biphasic platelet
aggregation.
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Figure 5. Concentration-dependent effects of cinnamon-derived cinnamaldehyde
on ADP-induced platelet aggregation. A) Cinnamaldehyde (10 µM) and ADP (10
µM) tested versus ADP-alone control; B) Cinnamaldehyde (100 µM) and ADP
tested versus ADP-only control. Arrows indicate the inflection point between
phase 1 and phase 2 aggregation. C) Summary data of concentration-dependent
effects of cinnamaldehyde on ADP-induced platelet aggregation. Using a paired
Student’s t-test, the percent responses of total, phase 1, and phase 2
aggregation of cinnamaldehyde were compared with respect to their control.
Statistical significance was accepted where p<0.05. No significant changes were
detected.
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Figure 6. Effect of vanilla-derived vanillin on ADP-induced platelet aggregation.
A) The representative curve indicating vanillin (100 µM) and ADP (10 µM) tested
versus ADP-alone control. Arrows indicate the inflection point between phase 1
and phase 2 aggregation. B) Summary data of effect of vanillin on ADP-induced
platelet aggregation. Using a paired Student’s t-test, the percent responses of
total, phase 1, and phase 2 aggregation of vanillin were compared with respect to
their control. Statistical significance was accepted where p<0.05. No significant
changes were detected.
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3.E. Direct effect of mint-derived menthol on ADP-induced phase 1 and
phase 2 platelet aggregation. The present study investigates menthol flavoring,
known to induce some cardiovascular-related events. Ciftçi et al. 2009 evaluated
cardiovascular outcomes associated with menthol (mentholated) tobacco
cigarettes in humans [77]. They found that mentholated cigarettes worsened
cardiovascular

outcomes

compared

with

non-mentholated

cigarettes

as

demonstrated by impaired ventricular diastolic function, exacerbated heart rate
(101.2 bpm compared with 83 bpm), increased in systolic blood pressure (130.7
mmHg compared with 118.0 mmHg), and increased stiffness of the carotid artery
(index of 5.7 compared with 2.2) [77]. We hypothesized that direct exposure to
menthol induces significant changes in biphasic platelet aggregation ex vivo. We
found that menthol exerted no effects on ADP-induced biphasic platelet
aggregation (Figure 7).
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Figure 7. Effect of mint-derived menthol on ADP-induced platelet aggregation. .
A) The representative curve indicating menthol (100 µM) and ADP (10 µM) tested
versus ADP-alone control. Arrows indicate the inflection point between phase 1
and phase 2 aggregation. B) Summary data of effect of menthol on ADP-induced
platelet aggregation. Using a paired Student’s t-test, the percent responses of
total, phase 1, and phase 2 aggregation of menthol were compared with respect
to their control. Statistical significance was accepted where p<0.05. No significant
changes were detected.
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3.F. Effect of acute MCS exposure via inhalation on C57BL/6 male mice.
Various physiological mechanisms have been proposed for tobacco smokeinduced CVD. Salahuddin et al. proposed that cigarette smoke is comprised of
oxidant gases and toxic chemicals that inevitably release and activate free radicals
that cause oxidative stress, increase inflammation, and decrease NO production
[78]. As a result of these effects, platelet activation and thrombosis are more likely
to occur. With this knowledge, we hypothesized that acute exposure to MCS will
lead to platelet activation in vivo as measured by increased formation of PLAs. To
test this hypothesis, C57BL/6 male mice were exposed to MCS (12 cigs/d, 4d) or
HEPA-filtered air (control; 4d, 6h/d). Immediately after final exposure, the mice
were euthanized and their peripheral blood was collected and prepared for flow
cytometric analyses for identification and quantification of CD45+/CD41+ PLAs.
Our results indicate that acute exposure to MCS yielded a significant increase in
PLA formation compared with air control (Figure 8). These data suggest that
exposure to MCS causes platelet activation.
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Figure 8. Effects of acute MCS exposure on PLAs in male mice. Flow cytometry
analysis was performed in order to identify CD45+/CD41+ PLAs in 100µL male
mouse blood following an acute 4d exposure to MCS (50% of smoke from 12-cigs
/ 6h; n=5,5). Representative flow cytometry dot plots of (A.i) control (HEPA-filtered
air) versus (A.ii) MCS-exposed mice are displayed. B) Summary data displays
each individual mouse exposed to either air or MCS. PLAs are characterized as
20,000 CD45/CD41 double positive events, located in quadrant 2 (Q2). The mice
exposed to MCS showed significant increase in PLAs compared with control
p=0.032 via Mann-Whitney U test.
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3.G. Effect of acute e-cig aerosol exposure via inhalation on C57BL/6 male
mice. As previous mentioned and shown in Conklin et al. 2018, we know that
MCS and e-cig aerosols have common aldehyde constituents [32]. Therefore, in
our study, we investigated if e-cig exposure induces platelet activation in a similar
fashion as our MCS study. We hypothesized that acute exposure to e-cig will
lead to platelet activation in vivo as assessed by increased formation of PLAs.
C57BL/6 male mice were exposed to e-cig aerosol (blu+; 4d, 6h/d) or HEPAfiltered air (control; 4d, 6h/d). Immediately after the final exposure, the mice were
euthanized, and their peripheral blood was collected and prepared for flow
cytometric analyses of CD45+/CD41+ PLAs. Our results indicate that acute
exposure to e-cig aerosol induced no change in PLA formation compared with air
control (Figure 9).
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Figure 9. Effects of acute e-cig exposure on PLAs in male mice. Flow cytometry
analysis was performed in order to identify CD45+/CD41+ PLAs in 100µL male
mouse blood following an acute 4d exposure to e-cig aerosol (blu+ Classic
Tobacco; 6h/d; n=10,10). Representative flow cytometry dot plots of (A.i) control
(HEPA-filtered air) versus (A.ii) e-cig-exposed mice are displayed. B) Summary
data displays each individual mouse exposed to either air or e-cig aerosol. PLAs
are characterized as 20,000 CD45/CD41 double positive events, located in
quadrant 2 (Q2). The mice exposed to e-cig aerosol showed no difference in PLAs
compared with control, p=0.273 via Mann-Whitney U test.
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3.H. Effect of acute exposure to formaldehyde via inhalation on C57BL/6
male mice. In order to assess the effects of formaldehyde on platelet activation,
we measured the concentration- and time-dependent exposure impacts on PLAs.
We hypothesized that acute (4d or 2-wk) exposure to formaldehyde will induce
platelet activation in vivo as assessed by increased formation of PLAs. C57BL/6
male mice were exposed to formaldehyde (2 or 5 ppm; 6h/d, 4d or 2-wk) or
HEPA-filtered air (control; 6h/d, 4d or 2-wk). Immediately after final exposure, the
mice were euthanized and their peripheral blood was collected and prepared for
flow cytometric analyses of CD45+/CD41+ PLAs. Our results indicate that male
mice acutely exposed to formaldehyde (2 ppm) had no alterations in PLA
formation compared with control (Figure 10). As Bhatnagar found that
formaldehyde concentrations above 2 ppm increased platelet count [35], we
hypothesized that by increasing the concentration, more PLA formation will
result. However, treatment with a formaldehyde concentration of 5 ppm still
exerted no change (Figure 11). However, the previous report of an increased
platelet count resulted from a longer duration (12d) of exposure [35]. Therefore,
we completed a two week exposure to a high concentration of formaldehyde,
hypothesizing this would change abundance of PLAs. However, we found no
changes in PLA formation compared with air controls (Figure 12).
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Figure 10. Effects of acute formaldehyde (2 ppm) exposure on PLAs in male mice.
Flow cytometry analysis was performed in order to identify CD45+/CD41+ PLAs in
100µL male mouse blood following an acute 4d exposure to formaldehyde (6h/d;
n=10,10). Representative flow cytometry dot plots of (A.i) control (HEPA-filtered
air) versus (A.ii) formaldehyde-exposed mice are displayed. B) Summary data
displays each individual mouse exposed to either air or formaldehyde. PLAs are
characterized as 20,000 CD45/CD41 double positive events, located in quadrant
2 (Q2). The mice exposed to formaldehyde showed no difference in PLAs
compared with control, p=0.597 via Mann-Whitney U test.
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Figure 11. Effects of acute formaldehyde (5 ppm) exposure on PLAs in male mice.
Flow cytometry analysis was performed in order to identify CD45+/CD41+ PLAs in
100µL male mouse blood following an acute 4d exposure to formaldehyde (6h/d;
n=6,8). Representative flow cytometry dot plots of (A.i) control (HEPA-filtered air)
versus (A.ii) formaldehyde-exposed mice are displayed. B) Summary data
displays each individual mouse exposed to either air or formaldehyde. PLAs are
characterized as 20,000 CD45/CD41 double positive events, located in quadrant
2 (Q2). The mice exposed to formaldehyde showed no difference in PLAs
compared with control, p=0.368 via Mann-Whitney U test.
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Figure 12. Effects of acute (2-wk) formaldehyde (5 ppm) exposure on PLAs in
male mice. Flow cytometry analysis was performed in order to identify
CD45+/CD41+ PLAs in 100µL male mouse blood following exposure to
formaldehyde (6h/d; n=10,10). Representative flow cytometry dot plots of (A.i)
control (HEPA-filtered air) versus (A.ii) formaldehyde-exposed mice are displayed.
B) Summary data displays each individual mouse exposed to either air or
formaldehyde. PLAs are characterized as 20,000 CD45/CD41 double positive
events, located in quadrant 2 (Q2). The mice exposed to formaldehyde showed no
difference in PLAs compared with control, p=0.678 via Mann-Whitney U test.
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3.I. Effect of acute exposure to formaldehyde via inhalation on C57BL/6
female mice. Like our previous studies, we measured the effects of
formaldehyde exposure on PLA outcomes in female mice. We hypothesized that
acute (4d) exposure to formaldehyde will induce platelet activation in vivo as
assessed by increased formation of PLAs. C57BL/6 female mice were exposed
to formaldehyde (2 or 5 ppm; 6h/d, 4d) or HEPA-filtered air (control; 6h/d, 4d).
Immediately after final exposure, the mice were euthanized, and their peripheral
blood was collected and prepared for flow cytometric analyses of CD45 +/CD41+
PLAs. Our results indicate that female mice acutely exposed to formaldehyde (2
ppm) demonstrated no alterations in PLA formation compared with control
(Figure 13). We also increased the concentration of formaldehyde, hypothesizing
that by increasing the concentration, more PLA formation will result. However, a
formaldehyde concentration of 5 ppm still exerted no change in PLA abundance
(Figure 14). Thus, there were no sex-dependent differences in PLA formation in
response to formaldehyde exposure.
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Figure 13. Effects of acute formaldehyde (2 ppm) exposure on PLAs in female
mice. Flow cytometry analysis was performed in order to identify CD45+/CD41+
PLAs in 100µL female mouse blood following an acute exposure to formaldehyde
(6h/d; n=8,10). Representative flow cytometry dot plots of (A.i) control (HEPAfiltered air) versus (A.ii) formaldehyde-exposed mice are displayed. B) Summary
data displays each individual mouse exposed to either air or formaldehyde. PLAs
are characterized as 20,000 CD45/CD41 double positive events, located in
quadrant 2 (Q2). The mice exposed to formaldehyde showed no difference in PLAs
compared with control, p=0.143 via Mann-Whitney U test.
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Figure 14. Effects of acute formaldehyde (5 ppm) exposure on PLAs in female
mice. Flow cytometry analysis was performed in order to identify CD45+/CD41+
PLAs in 100µL female mouse blood following an acute exposure to formaldehyde
(6h/d; n=6,8). Representative flow cytometry dot plots of (A.i) control (HEPAfiltered air) versus (A.ii) formaldehyde-exposed mice are displayed. B) Summary
data displays each individual mouse exposed to either air or formaldehyde. PLAs
are characterized as 20,000 CD45/CD41 double positive events, located in
quadrant 2 (Q2). The mice exposed to formaldehyde showed no difference in PLAs
compared with control, p=0.503 via Mann-Whitney U test.
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3.J. Effect of acute exposure to acetaldehyde via inhalation on C57BL/6
male mice. Acetaldehyde is a metabolite of ethanol. Investigators have
demonstrated that both compounds inhibit platelet aggregation [79, 80]. In order
to assess the effects of acetaldehyde in PLA formation, we performed a
concentration- and time-dependent exposure and analyzed the effects on
formation of PLAs via flow cytometry. We hypothesized that acute (4d or 2-wk)
exposure to acetaldehyde will inhibit platelet activation in vivo as measured by
decreased formation of PLAs. C57BL/6 male mice were exposed to
acetaldehyde (5 ppm; 6h/d, 4d or 2-wk) or HEPA-filtered air (control; 6h/d, 4d or
2-wk). Immediately after final exposure, the mice were euthanized, and their
peripheral blood was collected and prepared for flow cytometric analyses for
identification and quantification of CD45+/CD41+ PLAs. Our results indicate that
males acutely exposed to 5 ppm acetaldehyde yielded no change in PLA
formation compared with air control (Figure 15). By increasing the duration of
exposure, we were expecting to exacerbate PLA formation, but our results show
no effect in males (Figure 16).
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Figure 15. Effects of acute acetaldehyde (5 ppm) exposure on PLAs in male mice.
Flow cytometry analysis was performed in order to identify CD45+/CD41+ PLAs in
100µL male mouse blood following an acute exposure to acetaldehyde (6h/d;
n=5,5). Representative flow cytometry dot plots of (A.i) control (HEPA-filtered air)
versus (A.ii) acetaldehyde-exposed mice are displayed. B) Summary data
displays each individual mouse exposed to either air or acetaldehyde. PLAs are
characterized as 20,000 CD45/CD41 double positive events, located in quadrant
2 (Q2). The mice exposed to acetaldehyde showed no difference in PLAs
compared with control, p=0.056 via Mann-Whitney U test.
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Figure 16. Effects of acute (2-wk) acetaldehyde (5 ppm) exposure on PLAs in male
mice. Flow cytometry analysis was performed in order to identify CD45+/CD41+
PLAs in 100µL male mouse blood following exposure to acetaldehyde (6h/d;
n=10,10). Representative flow cytometry dot plots of (A.i) control (HEPA-filtered
air) versus (A.ii) acetaldehyde-exposed mice are displayed. B) Summary data
displays each individual mouse exposed to either air or acetaldehyde. PLAs are
characterized as 20,000 CD45/CD41 double positive events, located in quadrant
2 (Q2). The mice exposed to acetaldehyde showed no difference in PLAs
compared with control, p=0.473 via Mann-Whitney U test.
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3.K. Effect of acute exposure to acetaldehyde via inhalation on C57BL/6
female mice. We were interested in determining if the effects of inhaled
acetaldehyde exposure are sex dependent. We performed an acute exposure
using C57BL/6 female mice and analyzed the effects on formation of PLAs via
flow cytometry. These mice were exposed to acetaldehyde (5 ppm; 6h/d, 4d) or
HEPA-filtered air (control; 6h/d, 4d). Immediately after final exposure, the mice
were euthanized, and their peripheral blood was collected and prepared for flow
cytometric analyses for identification and quantification of CD45 +/CD41+ PLAs.
Our results indicate that acute exposure to acetaldehyde yielded no change in
PLA formation compared with air control. This effect was not sex-dependent
(Figure 17).
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Figure 17. Effects of acute acetaldehyde (5 ppm) exposure on PLAs in female
mice. Flow cytometry analysis was performed in order to identify CD45+/CD41+
PLAs in 100µL female mouse blood following exposure to acetaldehyde (6h/d;
n=5,6). Representative flow cytometry dot plots of (A.i) control (HEPA-filtered air)
versus (A.ii) acetaldehyde-exposed mice are displayed. B) Summary data
displays each individual mouse exposed to either air or acetaldehyde. PLAs are
characterized as 20,000 CD45/CD41 double positive events, located in quadrant
2 (Q2). The mice exposed to acetaldehyde showed no difference in PLAs
compared with control, p=0.573 via Mann-Whitney U test.
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3.L. Effect of acute and chronic exposure to crotonaldehyde via inhalation
on C57BL/6 male mice. Crotonaldehyde is an understudied toxicant. Both
acrolein and crotonaldehyde are present at high levels in cigarette smoke. Our
preliminary results indicate an increase in PLA formation in male mice acutely
exposed to MCS. Acrolein also exerts the same effect. Given that acrolein and
crotonaldehyde are similar compounds, we hypothesized that acute (4d) or
chronic (12-wk) exposure to crotonaldehyde will induce platelet activation in vivo
as assessed by increased formation of PLAs. C57BL/6 male mice were exposed
to crotonaldehyde (1 ppm; 6h/d, 4d or 12-wk) or HEPA-filtered air (control; 4d or
12-wk, 6h/d). Immediately after final exposure, the mice were euthanized and
their peripheral blood was collected and prepared for flow cytometric analyses of
CD45+/CD41+ PLAs. These data suggest that acute exposure to crotonaldehyde
significantly decreases PLA formation compared with air control. Chronic
exposure to crotonaldehyde yielded no change in PLA formation compared with
air control (Figure 18).
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Figure 18. Effects of (A) acute 4d or (B) chronic 12-wk crotonaldehyde exposure
in male mice. Flow cytometry analyses were performed in order to identify
CD45+/CD41+ PLAs in 100µL male mouse blood following exposure to
crotonaldehyde (1 ppm; 6h/d; n=9,9 and n=8,9, respectively in each study). PLAs
are characterized as 20,000 CD45/CD41 double positive events, located in
quadrant 2 (Q2). There is a significant decrease in PLA formation following acute
exposure to crotonaldehyde compared with control (HEPA-filtered air), p=0.042 via
Mann-Whitney U test. No changes in PLA formation resulted from chronic
exposure compared with control via Mann-Whitney U test.
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CHAPTER 4:
DISCUSSION
Here, we explored the influences of concentration-dependent acrolein and e-cig
flavoring additives (eugenol, cinnamaldehyde, vanillin, and menthol) on phasespecific ADP-induced platelet aggregation. When platelets activate, they undergo
biphasic activity. Primary aggregation, or phase 1, is a direct effect of the
stimulant/agonist. The stimulant induces a shape change, with subsequent
granule secretion. Secondary aggregation, or phase 2, occurs as a result of
platelet-platelet interactions due to the action of granule contents recruiting and
activating surrounding platelets. To our knowledge, no study has investigated the
direct effects of these compounds on phase 1 and phase 2 platelet aggregation
as a potential mechanism of total aggregation. By identifying what phase is more
affected, we will more fully understand the mechanism of these pro-thrombotic
agents.
Selley et al. investigated the effects of acrolein on ADP-induced
aggregation and found that acrolein exerted no effect on total aggregation
compared with control (ADP-alone) [75]. Our results in Figure 3 were able to
duplicate the published data, demonstrating that concentration-dependent effects
of acrolein on total aggregation did not differ compared with our control.
However, we observed a significant decrease in phase 1 activity at 10 and 30 µM
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and an increase in phase 2 at those same concentrations. We hypothesize that
at those levels, direct exposure causes rapid exocytosis of platelet granules, a
direct reflection of phase 1 activity. Thus, aggregation in phase 2 occurred much
faster, exhibited as an increase in response. Higher concentrations exerted no
effect on biphasic activity. This could be because the platelets became fixed prior
to ADP-induction.
Eugenol is a clove-oil derived flavoring compound [81]. This chemical is
also a potent anti-inflammatory agent [82-85], suggesting anti-platelet behavior.
In our results, we observed a decreased response of total and phase 2
aggregation with exposure to eugenol at increasing concentrations (Figure 4).
Upon close observation, it appears that we only see one phase of aggregation,
the primary phase. These results suggest that phase 2 is suppressed or
inhibited. In fact, at the highest concentration tested (100 µM), we observed
disaggregation in which our traces reversed post-phase 1 activity. Together, we
believe eugenol is an inhibitor of platelet aggregation.
Cinnamaldehyde is a cinnamon-derived flavoring compound. It is an
ingredient in the essential oils of cinnamon leaves and bark, and it has been
used as an additive in many aerosol fragrances as well as some household
products. Cinnamaldehyde is also a known peripheral vasodilator [86, 87]. When
the blood vessel is dilated, platelets tend to be inactive. This suggests that
cinnamaldehyde functions as an inhibitor of platelet aggregation. Some studies
have in fact proven the inhibitory effect of cinnamaldehyde [88, 89]. We
suspected to observe similar results as seen with eugenol. However, our result
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did not agree. We observed no change in total, phase 1, and phase 2
aggregation with exposure to cinnamaldehyde compared with control (Figure 5).
However, Takenaga et al. 1987 completed their study using collagen and
thrombin as their aggregating agents [89], whereas our study only used ADP.
This suggests that cinnamaldehydes effect on platelet aggregation is agonistdependent.
Vanillin, a vanilla-derived flavoring compound in e-cigs, exerts anti-platelet
aggregation effects in vitro via arachidonic acid-induction [90, 91]. Our
preliminary results indicate vanillin has no effect on ADP-induced aggregation as
well as no phase 1 or phase 2 responses (Figure 6). We hypothesize that vanillin
action is dependent upon arachidonic acid-receptor activation and not responsive
to ADP-receptor activation.
Menthol is mint-derived flavoring compound. Menthol triggers a cooling
sensation byway of dermal, oral, or inhalation exposures [92]. As indicated in the
literature, menthol inhibits collagen- and ADP-induced platelet aggregation in
vitro [93]. However, like our cinnamaldehyde responses, our results did not
compare with the literature. Additionally, phase 1 and phase 2 were unaffected
compared with control (Figure 7). Since total aggregation did not show inhibitory
responses, we believe our data is inconclusive and needs to be refined.
Though much of the data appear inconclusive, we do believe our data are
indicative of agonist-dependent effects. This suggests that certain e-cig-derived
flavoring compounds or aldehydes may act through different platelet receptors
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(e.g. ADP, collagen, thrombin, arachidonic acid, or epinephrine). This hypothesis
will be tested in future studies.
Also in this study, we investigated the level- and duration-dependent
effects of exposure to mainstream cigarette smoke (MCS), e-cig aerosol, and
aldehydes on PLA formation in vivo. Under the conditions tested, acute exposure
to MCS caused a significant increase in PLA formation in C57BL/6 male mice.
Nocella et al. 2018 and Carnevale et al. 2016 compared the impact of e-cigs with
conventional cigarettes in smokers and nonsmokers, specifically with endpoints
of oxidative stress, vascular function, and platelet function [94, 95]. These studies
revealed that exposure to conventional cigarettes induced changes in platelet
activation markers (sCD40L and sP-selectin) as well as increased collageninduced platelet aggregation [94]. However, exposure to e-cig did not exert the
same effects in these markers. Our lab has published that e-cig aerosols
generate unsaturated aldehyde at much lower levels than saturated aldehydes
[32], whereas MCS encompasses high concentrations of all four aldehydes.
Since we did not observe a change in PLA formation due to e-cig aerosol
exposure, we hypothesize that the unsaturated aldehydes may be the culprits or
agonists of PLA formation, not the saturated aldehydes.
To our knowledge, no study has explored the relationship between
saturated aldehyde exposure and PLA formation as measured by flow cytometry.
Under the conditions tested in our studies, exposure to formaldehyde (1 ppm or 5
ppm), at any duration, exerted no effect on PLA formation in both males and
females compared with control. Similarly, exposure to acetaldehyde exerted no
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significant changes. Acetaldehyde exerts inhibitory responses to platelet
aggregation in humans and rodents [79, 80]. In Figure 13, our Rank Sum Test
revealed acetaldehyde-induced a decrease in PLA formation compared with airexposed control with a p-value of 0.056. Though insignificant, we believe the
effect may be real if given a greater n.
As previously mentioned, Sithu et al. found that acute (1d, 6h) and subchronic (4d, 6h/d as indicated in the literature) exposure to acrolein (1 ppm)
increased PLA formation compared with air control [38]. We believed that
exposure to crotonaldehyde (1 ppm) would exert similar effects given the
similarities in chemical structure and reactivity. Under the conditions tested in our
study, acute exposure to crotonaldehyde resulted in an inhibitory response of
PLA formation compared with control (Figure 18A). A potential hypothesis is that
exposure to crotonaldehyde induces NO production. This action causes inhibitory
effects of platelet activation, which may help to explain the inhibitory response of
PLA formation in our study. More studies are needed to confirm this hypothesis.
Chronic exposure had no effect on PLA formation as compared with control. We
would also need to increase our n to validate these data.
CONCLUSION
Based on our studies, we conclude that exposure to some HPHCs such
as aldehyde and flavorings in tobacco-derived aerosols may play a significant
role in platelet activation. More research is required to explore the
pathophysiological mechanisms of platelet activation and how our HPHCs
influence those mechanisms.
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CHAPTER 5:
FUTURE DIRECTIONS
Given all tobacco products on the market, new possible health concerns
have been exposed. Aside from what is known about their respiratory effects, our
lab aims to uncover the adverse cardiovascular effects induced by exposure to
these products and their constituents. Future in vitro and in vivo studies will
explore the effects of these aldehydes with or without nicotine. Nicotine is a
highly addictive substance that accelerates heart rate as well as increases blood
pressure [23, 96-98]. Nicotine has been shown to inhibit platelet aggregation in
human platelets [99]. In combination with aldehydes, we will test if nicotine offers
a synergistic, inhibitory, or additive effect on platelet aggregation, PLA formation,
as well as other platelet activation markers.
We are furthermore proposing that the actions of the tobacco-derived
constituents on platelet activation are mediated via transient receptor potential
ankyrin-1 (TRPA1). For other future directions, we will test if the TRPA1 receptor
mediates platelet activation in each of our studies that displayed positive
outcomes. Investigators have postulated that effects observed due to exposure
to acrolein and/or other aldehydes are mediated via TRPA1-dependent activation
in the lungs and in the vasculature [72, 100, 101]. To our knowledge, there is no
data to demonstrate mechanistically that the effects of exposure to acrolein on
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platelet activation are mediated via TRPA1. TRPA1 is an irritant/pain responder
linked to pain and inflammation and is activated by environmental toxicants such
as cigarette smoke. Furthermore, TRPA1 protects against endogenous and
exogenous acrolein-induced cardiopulmonary toxicity in vivo at high
concentrations. Additionally, female wild-type mice were proven to be protected
from acrolein-induced mortality when compared with male wild-types [72]. We
hypothesize that the effects seen with acrolein-induced cardiopulmary toxicity are
both TRPA1- and sex-dependent. Previous studies have shown formaldehydeinduced lung inflammation is mediated via progesterone and estradiol, which is a
female hormone-specific effect [102-104]. Another study found that the TRPA1
channel may the target of sex-dependent issue related to migraine pain,
suggesting that women express more pain-related sensations compared to men
[105]. This may add to our hypothesis of sex-dependent effects of TRPA1mediated platelet activation. Our future directions are to test the relationship
between cigarette smoke exposure, TRPA1 and thrombosis. We will also
investigate sex-specific differences that are potentially TRPA1-dependent as
well.
The purpose of this research was to examine the effects of exposure to
MCS, e-cigs, flavorings, as well as the HPHCs on platelet activation as a marker
of thrombosis. Altogether, the results presented indicate that cigarette smoke can
exacerbate platelet pathophysiological outcomes. Our goal in the future is to
discover the potential mechanism in which tobacco-derived aerosols induce
platelet activation. Ultimately, there is a huge gap of knowledge concerning the
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effects of smoking and vaping on cardiovascular health, and we intend to bridge
together that understanding and combat CVD.

54

REFERENCES

1.
2.
3.
4.
5.

6.

7.

8.

9.
10.
11.
12.

13.

14.

15.

(NIH), N.I.o.H. Ischemic Heart Disease. Available from:
https://www.nhlbi.nih.gov/health-topics/ischemic-heart-disease.
(NIH), N.I.o.H. Cardiovascular Disease. 2017; Available from:
https://nccih.nih.gov/health/heart-disease.
(CDC), C.f.D.C.a.P., Coronary Artery Disease.
(AHA), A.H.A., Heart Disease and Stroke Statistics 2017 At-a-Glance. 2017.
National Center for Chronic Disease, P., S. Health Promotion Office on, and Health,
Reports of the Surgeon General, in The Health Consequences of Smoking-50 Years of
Progress: A Report of the Surgeon General. 2014, Centers for Disease Control and
Prevention (US): Atlanta (GA).
Olasky, S.J., D. Levy, and A. Moran, Second hand smoke and cardiovascular disease in
Low and Middle Income Countries: a case for action. Global heart, 2012. 7(2): p. 151160.e5.
Barnoya, J. and A. Navas-Acien, Protecting the world from secondhand tobacco smoke
exposure: where do we stand and where do we go from here? Nicotine & tobacco
research : official journal of the Society for Research on Nicotine and Tobacco, 2013.
15(4): p. 789-804.
Yankelevitz, D.F., et al., Second-Hand Tobacco Smoke in Never Smokers Is a Significant
Risk Factor for Coronary Artery Calcification. JACC: Cardiovascular Imaging, 2013. 6(6): p.
651-657.
(AHA), A.H.A., FACTS: What are you smoking? Smoking and Cardiovascular Disease
(CVD).
Bhatnagar, A., Environmental cardiology: studying mechanistic links between pollution
and heart disease. Circ Res, 2006. 99(7): p. 692-705.
(CDC), C.f.D.C.a.P., Smoking and Cardiovascular Disease.
Al-Qazzaz, N.K., et al., Cognitive impairment and memory dysfunction after a stroke
diagnosis: a post-stroke memory assessment. Neuropsychiatric disease and treatment,
2014. 10: p. 1677-1691.
Ambuj Roy, I.R., Samer Jabbour, Dorairaj Prabhakaran, Tobacco and Cardiovascular
Disease: A Summary of Evidence. Cardiovascular, Respiratory, and Related Disorders,
2017.
Hackshaw, A., et al., Low cigarette consumption and risk of coronary heart disease and
stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ (Clinical research
ed.), 2018. 360: p. j5855-j5855.
Banks, E., et al., Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal
and non-fatal outcomes in a large prospective Australian study. BMC Medicine, 2019.
17(1): p. 128.

55

16.

17.

18.

19.
20.

21.
22.

23.
24.

25.
26.
27.
28.

29.

30.

31.
32.

33.

Aune, D., et al., Tobacco smoking and the risk of sudden cardiac death: a systematic
review and meta-analysis of prospective studies. European journal of epidemiology,
2018. 33(6): p. 509-521.
Morris, P.B., et al., Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic
Cigarettes: Clinical Perspectives From the Prevention of Cardiovascular Disease Section
Leadership Council and Early Career Councils of the American College of Cardiology. J Am
Coll Cardiol, 2015. 66(12): p. 1378-91.
Morris, P.B., et al., Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic
Cigarettes. Clinical Perspectives From the Prevention of Cardiovascular Disease Section
Leadership Council and Early Career Councils of the American College of Cardiology,
2015. 66(12): p. 1378-1391.
Fairchild, A.L., R. Bayer, and J. Colgrove, The renormalization of smoking? E-cigarettes
and the tobacco "endgame". N Engl J Med, 2014. 370(4): p. 293-5.
Berg, C.J., et al., Attitudes toward E-Cigarettes, Reasons for Initiating E-Cigarette Use,
and Changes in Smoking Behavior after Initiation: A Pilot Longitudinal Study of Regular
Cigarette Smokers. Open journal of preventive medicine, 2014. 4(10): p. 789-800.
Bhatnagar, A., Are Electronic Cigarette Users at Increased Risk for Cardiovascular
Disease? JAMA Cardiology, 2017. 2(3): p. 237-238.
Farsalinos, K.E. and R. Polosa, Safety evaluation and risk assessment of electronic
cigarettes as tobacco cigarette substitutes: a systematic review. Therapeutic advances in
drug safety, 2014. 5(2): p. 67-86.
Benowitz, N.L. and A.D. Burbank, Cardiovascular toxicity of nicotine: Implications for
electronic cigarette use. Trends in cardiovascular medicine, 2016. 26(6): p. 515-523.
Tayyarah, R. and G.A. Long, Comparison of select analytes in aerosol from e-cigarettes
with smoke from conventional cigarettes and with ambient air. Regulatory Toxicology
and Pharmacology, 2014. 70(3): p. 704-710.
Chen, J., C. Bullen, and K. Dirks, A Comparative Health Risk Assessment of Electronic
Cigarettes and Conventional Cigarettes. Int J Environ Res Public Health, 2017. 14(4).
McNeill A BL, C.R., Hitchman SC, Hajek P, McRobbie H, E-cigarettes: an evidence update.
Public Health England, 2015: p. 1-113.
Sassano, M.F., et al., Evaluation of e-liquid toxicity using an open-source highthroughput screening assay. PLoS biology, 2018. 16(3): p. e2003904-e2003904.
Mishra, A., et al., Harmful effects of nicotine. Indian journal of medical and paediatric
oncology : official journal of Indian Society of Medical & Paediatric Oncology, 2015.
36(1): p. 24-31.
Onor, I.O., et al., Clinical Effects of Cigarette Smoking: Epidemiologic Impact and Review
of Pharmacotherapy Options. International journal of environmental research and public
health, 2017. 14(10): p. 1147.
Goniewicz, M.L., et al., Comparison of Nicotine and Toxicant Exposure in Users of
Electronic Cigarettes and Combustible Cigarettes. JAMA Network Open, 2018. 1(8): p.
e185937-e185937.
Ogunwale, M.A., et al., Aldehyde Detection in Electronic Cigarette Aerosols. ACS Omega,
2017. 2(3): p. 1207-1214.
Conklin, D.J., et al., Electronic cigarette-generated aldehydes: The contribution of e-liquid
components to their formation and the use of urinary aldehyde metabolites as
biomarkers of exposure. Aerosol Science and Technology, 2018. 52(11): p. 1219-1232.
Benowitz, N.L. and J.B. Fraiman, Cardiovascular effects of electronic cigarettes. Nat Rev
Cardiol, 2017. 14(8): p. 447-456.
56

34.

35.

36.

37.
38.
39.
40.

41.
42.
43.
44.

45.

46.
47.
48.
49.
50.
51.
52.

53.
54.
55.

Khlystov, A. and V. Samburova, Flavoring Compounds Dominate Toxic Aldehyde
Production during E-Cigarette Vaping. Environmental Science & Technology, 2016.
50(23): p. 13080-13085.
Bhatnagar, A., E-Cigarettes and Cardiovascular Disease Risk: Evaluation of Evidence,
Policy Implications, and Recommendations. Current Cardiovascular Risk Reports, 2016.
10(7): p. 24.
Luo, J., et al., Mechanisms of acrolein-induced myocardial dysfunction: implications for
environmental and endogenous aldehyde exposure. Am J Physiol Heart Circ Physiol,
2007. 293(6): p. H3673-84.
DeJarnett, N., et al., Acrolein exposure is associated with increased cardiovascular
disease risk. J Am Heart Assoc, 2014. 3(4).
Sithu, S.D., et al., Exposure to acrolein by inhalation causes platelet activation. Toxicol
Appl Pharmacol, 2010. 248(2): p. 100-10.
(NTP), N.T.P., Report on Carcinogens: Formaldehyde. 14.
Egle, J.L., Jr. and P.M. Hudgins, Dose-dependent sympathomimetic and cardioinhibitory
effects of acrolein and formaldehyde in the anesthetized rat. Toxicol Appl Pharmacol,
1974. 28(3): p. 358-66.
(NTP), N.T.P., Report on Carcinogens: Acetaldehyde. 1991(14).
Egle, J.L., Jr., Effects of inhaled acetaldehyde and propionaldehyde on blood pressure and
heart rate. Toxicol Appl Pharmacol, 1972. 23(1): p. 131-5.
Pawlak, D., B. Malinowska, and W. Buczko, Cardiovascular effects of acetaldehyde in
pithed rats. Pharmacology, 1992. 45(2): p. 83-9.
Egle, J.L., Jr., P.M. Hudgins, and F.M. Lai, Cardiovascular effects of intravenous
acetaldehyde and propionaldehyde in the anesthetized rat. Toxicol Appl Pharmacol,
1973. 24(4): p. 636-44.
Kupari, M., et al., Cardiovascular Effects of Acetaldehyde Accumulation after Ethanol
Ingestion: Their Modification by β-Adrenergic Blockade and Alcohol Dehydrogenase
Inhibition. Alcoholism: Clinical and Experimental Research, 1983. 7(3): p. 283-288.
(ATSDR), A.f.T.S.a.D.R., Toxicological Profile for Acrolein.
Agency, U.E.P., Acrolein. 2016.
Weber-Tschopp, A., et al., [Experimentally induced irritating effects of acrolein on men
(author's transl)]. Int Arch Occup Environ Health, 1977. 40(2): p. 117-30.
ATSDR, Toxic Substances Portal - Crotonaldehyde. 2014.
OSHA, Crotonaldehyde. 1990.
Fetterman, J.L., et al., Flavorings in Tobacco Products Induce Endothelial Cell
Dysfunction. Arterioscler Thromb Vasc Biol, 2018. 38(7): p. 1607-1615.
Wang, G.R., et al., Mechanism of platelet inhibition by nitric oxide: in vivo
phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase.
Proceedings of the National Academy of Sciences of the United States of America, 1998.
95(9): p. 4888-4893.
Riddell, D.R. and J.S. Owen, Nitric oxide and platelet aggregation. Vitam Horm, 1999. 57:
p. 25-48.
Nong, Z., et al., Nitric Oxide Inhalation Inhibits Platelet Aggregation and PlateletMediated Pulmonary Thrombosis in Rats. Circulation Research, 1997. 81(5): p. 865-869.
Samama, C.M.M.D.P., et al., Inhibition of Platelet Aggregation by Inhaled Nitric Oxide in
Patients with Acute Respiratory Distress Syndrome. Anesthesiology: The Journal of the
American Society of Anesthesiologists, 1995. 83(1): p. 56-65.

57

56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.

67.
68.

69.
70.

71.

72.
73.
74.
75.
76.

Gkaliagkousi, E., et al., Decreased platelet nitric oxide contributes to increased circulating
monocyte-platelet aggregates in hypertension. Eur Heart J, 2009. 30(24): p. 3048-54.
Ho-Tin-Noe, B., Y. Boulaftali, and E. Camerer, Platelets and vascular integrity: how
platelets prevent bleeding in inflammation. Blood, 2018. 131(3): p. 277-288.
Finsterbusch, M., et al., Measuring and interpreting platelet-leukocyte aggregates.
Platelets, 2018. 29(7): p. 677-685.
Thomas, D.P., Effect of Catecholamines on Platelet Aggregation caused by Thrombin.
Nature, 1967. 215(5098): p. 298-299.
Anfossi, G. and M. Trovati, Role of catecholamines in platelet function:
pathophysiological and clinical significance. Eur J Clin Invest, 1996. 26(5): p. 353-70.
Inoue, T., Cigarette Smoking as a Risk Factor of Coronary Artery Disease and its Effects
on Platelet Function. Tobacco Induced Diseases, 2004. 2(1): p. 2-2.
P, R.R.a.T., Chapter 3Platelet Adhesion to Vascular Walls. 2010.
Bhattacharyya, K.G.a.M., Overview of Platelet Physiology: Its Hemostatic and
Nonhemostatic Role in Disease Pathogenesis. 2014.
Cerletti, C., et al., Platelet-leukocyte interactions in thrombosis. Thromb Res, 2012.
129(3): p. 263-6.
Goniewicz, M.L., et al., Levels of selected carcinogens and toxicants in vapour from
electronic cigarettes. Tobacco Control, 2014. 23(2): p. 133.
Shields, P.G., et al., A Review of Pulmonary Toxicity of Electronic Cigarettes in the
Context of Smoking: A Focus on Inflammation. Cancer epidemiology, biomarkers &
prevention : a publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology, 2017. 26(8): p. 11751191.
Chun, L.F., et al., Pulmonary toxicity of e-cigarettes. Am J Physiol Lung Cell Mol Physiol,
2017. 313(2): p. L193-l206.
Shahab, L., et al., Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and
Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med, 2017.
166(6): p. 390-400.
Paniccia, R., et al., Platelet function tests: a comparative review. Vascular health and risk
management, 2015. 11: p. 133-148.
Conklin, D.J., et al., Biomarkers of Chronic Acrolein Inhalation Exposure in Mice:
Implications for Tobacco Product-Induced Toxicity. Toxicological Sciences, 2017. 158(2):
p. 263-274.
O'Toole, T.E., et al., Acrolein decreases endothelial cell migration and insulin sensitivity
through induction of let-7a. Toxicological sciences : an official journal of the Society of
Toxicology, 2014. 140(2): p. 271-282.
Conklin, D.J., et al., Role of TRPA1 in acute cardiopulmonary toxicity of inhaled acrolein.
Toxicol Appl Pharmacol, 2017. 324: p. 61-72.
Michelson, A.D. and P.E. Newburger, Platelets and leukocytes: aggregate knowledge.
Blood, 2007. 110(3): p. 794.
Sithu, S.D., et al., Platelet Sensitivity is Increased by Acrolein. The FASEB Journal, 2008.
22(1_supplement): p. 897.6-897.6.
Selley, M.L., et al., Effects of acrolein on human platelet aggregation. Chem Biol Interact,
1990. 76(1): p. 101-9.
Muthumalage, T., et al., Inflammatory and Oxidative Responses Induced by Exposure to
Commonly Used e-Cigarette Flavoring Chemicals and Flavored e-Liquids without
Nicotine. Front Physiol, 2017. 8: p. 1130.
58

77.
78.
79.
80.
81.
82.

83.

84.

85.

86.

87.

88.
89.

90.
91.
92.
93.

94.
95.
96.

Ciftci, O., et al., Mentholated cigarette smoking and brachial artery, carotid artery, and
aortic vascular function. Turk Kardiyol Dern Ars, 2009. 37(4): p. 234-40.
Salahuddin, S., D. Prabhakaran, and A. Roy, Pathophysiological Mechanisms of TobaccoRelated CVD. Global Heart, 2012. 7(2): p. 113-120.
Spertini, O., J. Hauert, and F. Bachmann, Reaction of acetaldehyde with human platelets.
Thromb Haemost, 1992. 67(1): p. 126-30.
Zoucas, E. and S. Bengmark, Effect of acetaldehyde on rat platelet aggregation in vivo
and in vitro. Res Exp Med (Berl), 1987. 187(1): p. 43-8.
USTPO, Eugenol enhancement of transdermal drug delivery. US Patent 4888362. 1989.
Barboza, J.N., et al., An Overview on the Anti-inflammatory Potential and Antioxidant
Profile of Eugenol. Oxidative medicine and cellular longevity, 2018. 2018: p. 39572623957262.
Ma, N., et al., Evaluation on antithrombotic effect of aspirin eugenol ester from the view
of platelet aggregation, hemorheology, TXB2/6-keto-PGF1α and blood biochemistry in
rat model. BMC veterinary research, 2016. 12(1): p. 108-108.
Mnafgui, K., et al., Anti-inflammatory, Antithrombotic and Cardiac Remodeling
Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar
Rat. Cardiovascular toxicology, 2016. 16(4): p. 336-344.
Raghavendra, R.H. and K.A. Naidu, Spice active principles as the inhibitors of human
platelet aggregation and thromboxane biosynthesis. Prostaglandins Leukot Essent Fatty
Acids, 2009. 81(1): p. 73-8.
Raffai, G., et al., Cinnamaldehyde and cinnamaldehyde-containing micelles induce
relaxation of isolated porcine coronary arteries: role of nitric oxide and calcium.
International journal of nanomedicine, 2014. 9: p. 2557-2566.
Aubdool, A.A., et al., TRPA1 activation leads to neurogenic vasodilatation: involvement
of reactive oxygen nitrogen species in addition to CGRP and NO. Br J Pharmacol, 2016.
173(15): p. 2419-33.
Huang, J., et al., Cinnamaldehyde reduction of platelet aggregation and thrombosis in
rodents. Thromb Res, 2007. 119(3): p. 337-42.
Takenaga, M., et al., In vitro effect of cinnamic aldehyde, a main component of
Cinnamomi Cortex, on human platelet aggregation and arachidonic acid metabolism. J
Pharmacobiodyn, 1987. 10(5): p. 201-8.
Lin, W.Y., et al., Anti-platelet aggregation constituents from Gynura elliptica.
Phytochemistry, 2000. 53(8): p. 833-6.
Lin, W.Y., et al., Anti-platelet aggregation and chemical constituents from the rhizome of
Gynura japonica. Planta Med, 2003. 69(8): p. 757-64.
Eccles, R., Menthol and related cooling compounds. J Pharm Pharmacol, 1994. 46(8): p.
618-30.
Murayama, M. and K.K. Kumaroo, Inhibitors of ex vivo aggregation of human platelets
induced by decompression, during reduced barometric pressure. Thromb Res, 1986.
42(4): p. 511-6.
Nocella, C., et al., Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet
Function. American Journal of Cardiology, 2018. 122(9): p. 1477-1481.
Carnevale, R., et al., Acute Impact of Tobacco vs Electronic Cigarette Smoking on
Oxidative Stress and Vascular Function. Chest, 2016. 150(3): p. 606-12.
Benowitz, N.L., Safety of nicotine in smokers with hypertension*. American Journal of
Hypertension, 2001. 14(7): p. 731-732.

59

97.
98.
99.
100.
101.

102.

103.

104.
105.

Najem, B., et al., Acute Cardiovascular and Sympathetic Effects of Nicotine Replacement
Therapy. Hypertension, 2006. 47(6): p. 1162-1167.
Pickering, T.G., The Effects of Smoking and Nicotine Replacement Therapy on Blood
Pressure. The Journal of Clinical Hypertension, 2001. 3(5): p. 319-321.
Brinson, K., Effect of nicotine on human blood platelet aggregation. Atherosclerosis,
1974. 20(1): p. 137-140.
Conklin, D.J., Acute cardiopulmonary toxicity of inhaled aldehydes: role of TRPA1. Ann N
Y Acad Sci, 2016. 1374(1): p. 59-67.
Jin, L., et al., Formaldehyde Induces Mesenteric Artery Relaxation via a Sensitive
Transient Receptor Potential Ankyrin-1 (TRPA1) and Endothelium-Dependent
Mechanism: Potential Role in Postprandial Hyperemia. Frontiers in physiology, 2019. 10:
p. 277-277.
Lino-dos-Santos-Franco, A., et al., Differential effects of female sex hormones on cellular
recruitment and tracheal reactivity after formaldehyde exposure. Toxicol Lett, 2011.
205(3): p. 327-35.
Lino-dos-Santos-Franco, A., et al., The putative role of ovary removal and progesterone
when considering the effect of formaldehyde exposure on lung inflammation induced by
ovalbumin. Clinics (Sao Paulo, Brazil), 2013. 68(12): p. 1528-1536.
Keselman, A., et al., Estrogen Signaling Contributes to Sex Differences in Macrophage
Polarization during Asthma. The Journal of Immunology, 2017. 199(5): p. 1573.
Artero-Morales, M., S. González-Rodríguez, and A. Ferrer-Montiel, TRP Channels as
Potential Targets for Sex-Related Differences in Migraine Pain. Frontiers in molecular
biosciences, 2018. 5: p. 73-73.

60

APPENDICES
LIST OF ABBREVIATIONS

ADP

Adenosine diphosphate

AHA

American Heart Association

ATP

Adenosine triphosphate

CBC

Complete blood count

CDC

Centers for Disease Control and Prevention

CHD

Coronary heart disease

CSR

Cigarette-smoking robot

CVD

Cardiovascular disease

DVT

Deep vein thrombosis

E-cig

Electronic cigarette

ENDS

Electronic nicotine delivery systems

HPHCs

Harmful or potentially harmful constituents

MCS

Mainstream cigarette smoke

MI

Myocardial infarction

NO

Nitric oxide

NTP

National Toxicology Program

OHSA

Occupational Safety and Health Administration

PE

Pulmonary embolism

PG

Propylene glycol

PPP

Platelet poor plasma

PRP

Platelet rich plasma

PLA

Platelet-leukocyte aggregate

ISO

International Standard of Organization
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TRPA1

Transient receptor potential ankyrin-1

TSP

Total suspended particulate

VG

Vegetable glycerin
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